
               
               
               
                  12Â  CLINICAL PHARMACOLOGY 

               
               
               
                  
                     
                     
                     
                        12.1 Mechanism of Action 

                     
                     
                        Clonidine stimulates alpha2-adrenergic receptors in the brain. Clonidine is not a central nervous system stimulant. The mechanism of action of clonidine in ADHD is not known.
                     
                     
                  
               
               
                  
                     
                     
                     
                        12.2 Pharmacodynamics 

                     
                     
                        Clonidine is a known antihypertensive agent. By stimulating alpha2-adrenergic receptors in the brain stem, clonidine reduces sympathetic outflow from the central nervous system and decreases peripheral resistance, renal vascular resistance, heart rate, and blood pressure.
                     
                     
                  
               
               
                  
                     
                     
                     
                        12.3 Pharmacokinetics 
                     
                     
                        
                           
                              Single-dose Pharmacokinetics in Adults
                           
                        
                        Immediate-release clonidine hydrochloride and clonidine hydrochloride extended-release have different pharmacokinetic characteristics; dose substitution on a milligram for milligram basis will result in differences in exposure. A comparison across studies suggests that the Cmax is 50% lower for clonidine hydrochloride extended-release compared to immediate-release clonidine hydrochloride.
                        Following oral administration of an immediate release formulation, plasma clonidine concentration peaks in approximately 3 to 5 hours and the plasma half- life ranges from 12 to 16 hours. The half-life increases up to 41 hours in patients with severe impairment of renal function. Following oral administration about 40 to 60% of the absorbed dose is recovered in the urine as unchanged drug in 24 hours.
                        About 50% of the absorbed dose is metabolized in the liver. Although studies of the effect of renal impairment and studies of clonidine excretion have not been performed with clonidine hydrochloride extended-release, results are likely to be similar to those of the immediate release formulation.
                        The pharmacokinetic profile of clonidine hydrochloride extended-release tablet administration was evaluated in an open-label, three-period, randomized, crossover study of 15 healthy adult subjects who received three single-dose regimens of clonidine: 0.1 mg of clonidine hydrochloride extended-release tablets under fasted conditions, 0.1 mg of clonidine hydrochloride extended-release tablets following a high fat meal, and 0.1 mg of clonidine hydrochloride immediate-release under fasted conditions. Treatments were separated by one-week washout periods.
                        Mean concentration-time data from the 3 treatments are shown in Table 7 and Figure 1. After administration of clonidine hydrochloride extended-release tablets, maximum clonidine concentrations were approximately 50% of the clonidine hydrochloride immediate-release maximum concentrations and occurred approximately 5 hours later relative to clonidine hydrochloride immediate-release. Similar elimination half-lives were observed and total systemic bioavailability following clonidine hydrochloride extended-release tablets was approximately 89% of that following clonidine hydrochloride immediate-release.
                        Food had no effect on plasma concentrations, bioavailability, or elimination half-life.
                        


                        



                           
                              
                                 Figure 1: Mean Clonidine Concentration-Time Profiles after Single Dose Administration
                              
                           
                        
                        
                           
                              Multiple-dose Pharmacokinetics in Children and Adolescents
                           
                        
                        Plasma clonidine concentrations in children and adolescents (0.1 mg bid and 0.2 mg bid) with ADHD are greater than those of adults with hypertension with children and adolescents receiving higher doses on a mg/kg basis. Body weight normalized clearance (CL/F) in children and adolescents was higher than CL/F observed in adults with hypertension. Clonidine concentrations in plasma increased with increases in dose over the dose range of 0.2 to 0.4 mg/day. Clonidine CL/F was independent of dose administered over the 0.2 to 0.4 mg/day dose range. Clonidine CL/F appeared to decrease slightly with increases in age over the range of 6 to 17 years, and females had a 23% lower CL/F than males. The incidence of "sedation-like" AEs (somnolence and fatigue) appeared to be independent of clonidine dose or concentration within the studied dose range in the titration study. Results from the add-on study showed that clonidine CL/F was 11% higher in patients who were receiving methylphenidate and 44% lower in those receiving amphetamine compared to subjects not on adjunctive therapy.
                     
                     
                     
                        
                           1
                           
                              
                           
                        
                     
                  
               
            
         